HAYA Therapeutics
Biotechnology ResearchVaud, Switzerland51-200 Employees
HAYA Therapeutics develops RNA-guided therapeutics that aim to reprogram disease-driving cell states by targeting the regulatory genome, with a focus on cardiovascular disease and cancer. It investigates long non-coding RNAs and other regulatory features to gain insight into cell-state biology and disease processes. The lead candidate, HTX-001, is designed to target Wisper, a cardiac lncRNA associated with heart failure. The company aims to deliver disease-modifying therapies that balance efficacy, safety, and accessibility compared with current options. Headquartered in Lausanne, in the Vaud region, within the Biopôle life sciences park, with laboratory work conducted in San Diego at Lilly Gateway Labs, the company operates in the biotechnology research sector. Its pipeline includes tissue-specific lncRNA targets for diseases in the lungs and solid tumor microenvironments, and it has pursued collaborations to advance RNA-based therapies, including a partnership with Eli Lilly on obesity efforts.
1-888-653-2347 
support@leadiq.com 
